Stock Scorecard
Stock Summary for LAVA Therapeutics NV (LVTX) - $2.73 as of 4/27/2024 5:15:11 AM EST
Total Score
9 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for LVTX
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for LVTX
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for LVTX
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for LVTX
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for LVTX
Financial Details for LVTX
Company Overview |
|
---|---|
Ticker | LVTX |
Company Name | LAVA Therapeutics NV |
Country | USA |
Description | Lava Therapeutics BV, a biotechnology company, is dedicated to developing a portfolio of gamma-delta bispecific T-cell activators (gamma-delta bsTCE) for the treatment of solid tumors and hematologic malignancies based on its platform. The company is headquartered in Utrecht, the Netherlands. |
Sector Name | LIFE SCIENCES |
Industry Name | PHARMACEUTICAL PREPARATIONS |
Most Recent Quarter | 12/31/2023 |
Next Earnings Date | 6/13/2024 |
Stock Price History |
|
Last Day Price | 2.73 |
Last Day Price Updated | 4/27/2024 5:15:11 AM EST |
Last Day Volume | 49,932 |
Average Daily Volume | 299,917 |
52-Week High | 4.21 |
52-Week Low | 1.13 |
Last Price to 52 Week Low | 141.59% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 79.17 |
Sector PE | 56.64 |
5-Year Average PE | -1.01 |
Free Cash Flow Ratio | 1.63 |
Industry Free Cash Flow Ratio | 12.71 |
Sector Free Cash Flow Ratio | 30.65 |
Current Ratio Most Recent Quarter | 6.62 |
Total Cash Per Share | 1.68 |
Book Value Per Share Most Recent Quarter | 1.95 |
Price to Book Ratio | 1.61 |
Industry Price to Book Ratio | 5.66 |
Sector Price to Book Ratio | 22.15 |
Price to Sales Ratio Twelve Trailing Months | 12.16 |
Industry Price to Sales Ratio Twelve Trailing Months | 5.48 |
Sector Price to Sales Ratio Twelve Trailing Months | 5.17 |
Share Statistics |
|
Total Shares Outstanding | 26,289,100 |
Market Capitalization | 71,769,243 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | -31.55% |
Reported EPS 12 Trailing Months | -1.57 |
Reported EPS Past Year | 0.00 |
Reported EPS Prior Year | -1.59 |
Net Income Twelve Trailing Months | -41,973,999 |
Net Income Past Year | -41,974,000 |
Net Income Prior Year | -31,907,000 |
Quarterly Revenue Growth YOY | -86.60% |
5-Year Revenue Growth | 0.00% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 44,230,999 |
Total Cash Past Year | 44,231,000 |
Total Cash Prior Year | 100,333,000 |
Net Cash Position Most Recent Quarter | 44,230,999 |
Net Cash Position Past Year | 39,591,000 |
Long Term Debt Past Year | 4,640,000 |
Long Term Debt Prior Year | 4,640,000 |
Total Debt Most Recent Quarter | 0 |
Equity to Debt Ratio Past Year | 0.92 |
Equity to Debt Ratio Most Recent Quarter | 1.00 |
Total Stockholder Equity Past Year | 51,178,000 |
Total Stockholder Equity Prior Year | 86,040,000 |
Total Stockholder Equity Most Recent Quarter | 51,177,999 |
Options |
|
Put/Call Ratio | 0.00 |
Has Options | False |
Liquidity Rating | None |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | -0.03 |
MACD Signal | 0.03 |
20-Day Bollinger Lower Band | 0.94 |
20-Day Bollinger Middle Band | 2.26 |
20-Day Bollinger Upper Band | 3.58 |
Beta | 0.63 |
RSI | 45.19 |
50-Day SMA | 1.93 |
200-Day SMA | 0.00 |
System |
|
Modified | 4/27/2024 5:15:12 AM EST |